LIMD2

Across TCGA pan-cancer cohorts, LIMD2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LIMD2 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LIMD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LIMD2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where LIMD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.852	0.988	.016	11	view →
PDAC	OS	Median	III,IV	0.343	0.833	.002	11	view →
LUAD	DFS	Quartile	All	0.848	0.441	.001	10	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.177	.024	2	view →
GBM	OS	Median	All	0.818	0.892	.039	1	view →
LSCC	DFS	Quartile	II,III,IV	0.603	0.933	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LIMD2–HNSC (DFS)

Open the HNSC breakdown →